Spironolactone in Diabetic Nephropathy

Steno Diabetes Center Copenhagen48 enrolled

Overview

The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetic Nephropathy

Interventions

SpironolactoneDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes Mellitus * Diabetic Nephropathy * Glomerular filtration rate \> 30 ml/min/1.73 m2 * Blood pressure \> 130/80 mm Hg Exclusion Criteria: * Child bearing potential * Plasma-potassium \>4.5 mmol/l * Breastfeeding * Abuse of alcohol or drugs * Non-diabetic kidney disease

Locations (1)

Steno Diabetes Center

Gentofte Municipality, Denmark

Outcomes

Primary Outcomes

Changes in albuminuria

Changes in blood pressure

Secondary Outcomes

Changes in glomerular filtration rate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.